
CLAIMS

WHAT IS CLAIMED:

1. A compound of Formula (I) or a pharmaceutically salt, co-crystal or solvate thereof:



(I)

wherein:

R^1 is $-CH_3$, $-CD_3$, $-CHD_2$, or $-CH_2D$;

R^2 is hydrogen or -D;


R^3 is hydrogen or -D;

R^4 is hydrogen, $-CH_2CH_3$; $-CD_2CD_3$; $-CD_2CH_3$; $-CH_2CD_3$; $-CDHCH_3$; $-CH_2CDH_2$; $-CH_2CD_2H$; $-CD_2CDH_2$; $-CD_2CD_2H$; $-CDHCD_3$; $-CDHCDH_2$; or $-CDHCD_2H$;


R^5 is hydrogen, $-CH_2CH_3$; $-CD_2CD_3$; $-CD_2CH_3$; $-CH_2CD_3$; $-CDHCH_3$; $-CH_2CDH_2$; $-CH_2CD_2H$; $-CD_2CDH_2$; $-CD_2CD_2H$; $-CDHCD_3$; $-CDHCDH_2$; or $-CDHCD_2H$; and

wherein at least one of R^1, R^2, R^3, R^4, or R^5, comprises at least one deuterium atom.


2. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:




3. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:




4. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:




5. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:




6. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:




7. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:




8. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:




9. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:



10. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:



11. A compound or a pharmaceutically acceptable salt, co-crystal or solvate thereof, that is:



12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, co-crystal or solvate thereof, wherein the positions represented as D have deuterium enrichment of at least 98%.
13. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, co-crystal or solvate thereof, wherein the positions represented as D have deuterium enrichment of at least 90%.
14. A pharmaceutical composition, comprising: a compound of any one of claims 1-13, or a pharmaceutically acceptable salt, co-crystal or solvate thereof, and a pharmaceutically acceptable carrier.

15. A method of treating Parkinson's disease or a movement disorder associated with Parkinson's disease in a subject in need thereof, comprising: administering to the subject the compound of any one of claims 1-13 or the pharmaceutical composition of claim 14.
16. A method of treating Parkinson's disease or a movement disorder associated with Parkinson's disease in a subject in need thereof, comprising: administering to the subject a therapeutically effective combination of (a) the compound of any one of claims 1-13 or the pharmaceutical composition of claim 14, and (b) an additional therapeutic agent.
17. The method of claim 16, wherein the additional therapeutic agent is a dopamine precursor.
18. The method of claim 17, wherein the dopamine precursor is levodopa.
19. The method of claim 16, wherein the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine, or a combination thereof.
20. The method of claim 16, wherein the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone.
21. The method of claim 16, wherein the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
22. The method of claim 16, wherein the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
23. The method of claim 15 or 16, wherein the movement disorder is dyskinesia.
24. The method of claim 23, wherein the dyskinesia is levodopa-induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
25. The method of claim 15 or 16, wherein the movement disorder is dystonia.
26. The method of claim 25, wherein the dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
27. The method of claim 15 or 16, wherein the movement disorder is akathisia.
28. The method of claim 27, wherein the akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal akathisia.
29. The method of claim 15 or 16, wherein the subject is diagnosed with Parkinson's disease.
30. A pharmaceutical combination for use for the treatment or prevention of Parkinson's disease, or a movement disorder associated with Parkinson's disease, in a subject in need thereof, comprising: a therapeutic combination of:
    (a) a compound of any one of claims 1-13 or the pharmaceutical composition of claim 14; and
    (b) an additional therapeutic agent for treating Parkinson's disease.
31. The pharmaceutical combination of claim 30, wherein the additional therapeutic agent is a dopamine precursor.
32. The pharmaceutical combination of claim 31, wherein the dopamine precursor is levodopa.

33. The pharmaceutical combination of claim 30, wherein the additional therapeutic agent is a dopamine agonist comprising pramipexole, ropinirole, rotigotine, pergolide, bromocriptine, piribedile, lisuride, or apomorphine.
34. The pharmaceutical combination of claim 30, wherein the additional therapeutic agent is a Catechol O-methyl transferase (COMT) inhibitor comprising entacapone, tolcapone, or opicapone.
35. The pharmaceutical combination of claim 30, wherein the additional therapeutic agent is a monoamine oxidase B (MAOB) inhibitor comprising selegiline or rasagiline.
36. The pharmaceutical combination of claim 30, wherein the additional therapeutic agent is a dopa decarboxylase inhibitor comprising carbidopa or benserazide.
37. The pharmaceutical combination of claim 30, wherein the movement disorder is dyskinesia.
38. The pharmaceutical combination of claim 37, wherein the dyskinesia is levodopa-induced dyskinesia (LID), diphasic dyskinesia, or peak-dose dyskinesia.
39. The pharmaceutical combination of claim 30, wherein the movement disorder is dystonia.
40. The pharmaceutical combination of claim 39, wherein the dystonia is generalized dystonia, focal dystonia, segmental dystonia, or acute dystonia.
41. The pharmaceutical combination of claim 30, wherein the movement disorder is akathisia.
42. The pharmaceutical combination of claim 41, wherein the akathisia is acute akathisia, chronic akathisia, pseudoakathisia, or withdrawal akathisia.
43. The pharmaceutical combination of claim 30, wherein the subject is diagnosed with Parkinson's disease.